Pacira BioSciences Appoints Four New Independent Directors to its Board of Directors

-- Enhances diversity and expertise in key areas including scientific, commercial, and financial --

TAMPA, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointments of Marcelo Bigal, MD, PhD, Abraham Ceesay, Michael Yang, and Alethia Young, to its Board of Directors effective immediately.

“We are pleased to welcome these four highly seasoned executives to our Board of Directors, whose experience will enhance our board as we advance on our strategic objectives across multiple key areas,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences.

Paul Hastings, Lead Independent Director of the Pacira Board, added, “The addition of these new directors underscores our commitment to ensuring strong corporate governance by maintaining a diversity of skills, experience, and perspectives on our board. We look forward to their contributions going forward as we continue to build upon our leadership position in non-opioid pain management.”

Each of the new directors adds diversity of experience and background to the Pacira board of directors, while also enhancing racial and gender diversity. Following these director appointments, Pacira will have 12 experienced directors, all with relevant industry experience.

About Marcelo Bigal, MD, PhD

Dr. Bigal is the President and Chief Executive Officer of Ventus Therapeutics and brings extensive experience in neurology to the Pacira Board of Directors. He has published over 330 peer-reviewed papers in the field of neurology, as well as five books. He has been recognized by the American Academy of Neurology with the Harold G. Wolff Award for excellence in research in neurology.

Dr. Bigal has over 15 years of pharmaceutical experience spanning research and development; medical affairs; and scientific affairs. Prior to Ventus, he was CMO and Head of Specialty Research and Development at Teva Pharmaceuticals, as well as CMO at Labrys Biologicals, leading the team that developed fremanezumab (AJOVY) for several forms of migraine, as well as deutetrabenazine (AUSTEDO) for the treatment of Huntington's disease and tardive dyskinesia, as well as other medicines in neurology, psychiatry, pain, and respiratory diseases approved in the US, Canada, and EU.